Westside Investment Management Inc. Lowers Position in Harrow, Inc. (NASDAQ:HROW)

Westside Investment Management Inc. cut its stake in Harrow, Inc. (NASDAQ:HROWFree Report) by 1.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 163,541 shares of the company’s stock after selling 2,403 shares during the quarter. Harrow accounts for about 1.2% of Westside Investment Management Inc.’s portfolio, making the stock its 20th biggest position. Westside Investment Management Inc. owned approximately 0.46% of Harrow worth $5,487,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Brookstone Capital Management purchased a new stake in shares of Harrow in the fourth quarter worth approximately $275,000. JPMorgan Chase & Co. increased its position in shares of Harrow by 443.1% during the third quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock valued at $10,717,000 after acquiring an additional 194,480 shares during the last quarter. Principal Financial Group Inc. purchased a new stake in shares of Harrow during the third quarter valued at approximately $329,000. Virtu Financial LLC purchased a new stake in shares of Harrow during the third quarter valued at approximately $271,000. Finally, Geode Capital Management LLC increased its position in shares of Harrow by 0.6% during the third quarter. Geode Capital Management LLC now owns 722,730 shares of the company’s stock valued at $32,500,000 after acquiring an additional 3,960 shares during the last quarter. 72.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on HROW shares. Craig Hallum increased their price target on Harrow from $45.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, October 4th. Lake Street Capital increased their price target on Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, October 4th. Finally, B. Riley decreased their price target on Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research report on Wednesday, December 4th.

Read Our Latest Stock Analysis on HROW

Harrow Stock Performance

Shares of HROW opened at $36.01 on Wednesday. The firm has a market cap of $1.28 billion, a PE ratio of -38.27 and a beta of 0.72. The stock’s fifty day moving average price is $37.79 and its two-hundred day moving average price is $39.02. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow, Inc. has a 1 year low of $9.13 and a 1 year high of $59.23.

Harrow Profile

(Free Report)

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Featured Stories

Want to see what other hedge funds are holding HROW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harrow, Inc. (NASDAQ:HROWFree Report).

Institutional Ownership by Quarter for Harrow (NASDAQ:HROW)

Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.